In the past week, JANX stock has gone up by 5.76%, with a monthly decline of -22.17% and a quarterly plunge of -31.66%. The volatility ratio for the week is 7.24%, and the volatility levels for the last 30 days are 7.84% for Janux Therapeutics Inc The simple moving average for the past 20 days is -10.09% for JANX’s stock, with a -41.40% simple moving average for the past 200 days.
Is It Worth Investing in Janux Therapeutics Inc (NASDAQ: JANX) Right Now?
The 36-month beta value for JANX is at 3.04. Analysts have varying views on the stock, with 11 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for JANX is 49.57M, and currently, shorts hold a 19.47% of that float. The average trading volume for JANX on May 22, 2025 was 999.40K shares.
JANX) stock’s latest price update
The stock price of Janux Therapeutics Inc (NASDAQ: JANX) has plunged by -0.64 when compared to previous closing price of 24.77, but the company has seen a 5.76% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-05-15 that SAN DIEGO–(BUSINESS WIRE)—- $JANX–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. “Janeen’s unique blend of corporate development, strategic execution, and cli.
Analysts’ Opinion of JANX
Many brokerage firms have already submitted their reports for JANX stocks, with H.C. Wainwright repeating the rating for JANX by listing it as a “Buy.” The predicted price for JANX in the upcoming period, according to H.C. Wainwright is $70 based on the research report published on December 03, 2024 of the previous year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see JANX reach a price target of $100, previously predicting the price at $82. The rating they have provided for JANX stocks is “Buy” according to the report published on December 03rd, 2024.
Leerink Partners gave a rating of “Outperform” to JANX, setting the target price at $79 in the report published on November 22nd of the previous year.
JANX Trading at -13.32% from the 50-Day Moving Average
After a stumble in the market that brought JANX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.68% of loss for the given period.
Volatility was left at 7.84%, however, over the last 30 days, the volatility rate increased by 7.24%, as shares sank -23.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.89% lower at present.
During the last 5 trading sessions, JANX rose by +5.41%, which changed the moving average for the period of 200-days by -34.11% in comparison to the 20-day moving average, which settled at $27.37. In addition, Janux Therapeutics Inc saw -54.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JANX starting from Meyer Andrew Hollman, who sale 3,333 shares at the price of $32.03 back on May 01 ’25. After this action, Meyer Andrew Hollman now owns 82,139 shares of Janux Therapeutics Inc, valued at $106,745 using the latest closing price.
ANDREW MEYER, the Officer of Janux Therapeutics Inc, proposed sale 3,333 shares at $33.20 during a trade that took place back on May 01 ’25, which means that ANDREW MEYER is holding shares at $110,656 based on the most recent closing price.
Stock Fundamentals for JANX
Current profitability levels for the company are sitting at:
- -12.17 for the present operating margin
- 0.95 for the gross margin
The net margin for Janux Therapeutics Inc stands at -8.33. The total capital return value is set at -0.11. Equity return is now at value -9.32, with -8.94 for asset returns.
Based on Janux Therapeutics Inc (JANX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -2.03.
Currently, EBITDA for the company is -98.85 million with net debt to EBITDA at 0.46. When we switch over and look at the enterprise to sales, we see a ratio of 150.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 58.47.
Conclusion
In conclusion, Janux Therapeutics Inc (JANX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
